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Abstract 
Hepatic elimination is a function of the interplay between different processes such as sinusoidal uptake, 
intracellular metabolism, canalicular (biliary) secretion, and sinusoidal efflux. In this review, we outline 
how drugs can be classified according to their in vitro determined clearance mechanisms using the 
extended clearance model as a reference. The approach enables the determination of the rate-
determining hepatic clearance step. Some successful applications will be highlighted, together with a 
discussion on the major consequences for the pharmacokinetics and the drug-drug interaction potential of 
drugs. Special emphasize is put on the role of passive permeability and active transport processes in 
hepatic elimination. 
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Extended clearance model 
Historically, hepatic clearance models assumed that (i) the unbound drug concentration in blood is 
determining the hepatic clearance (metabolism and/or biliary excretion) and that (ii) there is no membrane 
transport barrier limiting access to the enzymes or transporters in the hepatocyte. Improved models, 
however, reflect the physiological reality more precisely. In the liver drugs first have to overcome the 
membrane barrier separating the blood in the sinusoid from the cytosol of the hepatocytes. Permeation 
across this barrier might occur by passive diffusion and/or active carrier-mediated transport. Once in the 
cytosol drugs are subject to metabolism, efflux transporter-mediated canalicular (biliary) secretion and/or 
back-flux (active or passive) into the sinusoid. Consequently, generally referred as the extended clearance 
model (ECM), the overall hepatic intrinsic drug clearance (CLh,int) can be described as the interplay between 
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where, PSinf,act and PSinf,pas are the active and passive hepatic influx clearances from the blood, respectively, 
CLint,sec is the intrinsic biliary secretion clearance, and CLint,met is the intrinsic metabolic clearance. PSeff,act and 
PSeff,pas describe the active and passive sinusoidal efflux from the hepatocytes back into the blood, 
respectively. PSinf is the sum of PSinf,act and PSinf,pas, PSeff is the sum of PSeff,act and PSeff,pas, CLint is the sum of 
CLint,sec and CLint,met and CLint,h is the overall intrinsic hepatic clearance. 
The extended clearance model allows the identification of the rate-determining hepatic clearance step 
for a given drug molecule [1]. Depending on the relative contributions of the individual processes in Eq. (1), 
four different cases can be distinguished (Fig. 1). While (passive) hepatic uptake is the rate-determining 
step for ECM class 1 compounds, the sum of metabolism and efflux transporter-mediated biliary 
elimination is predicted to be the rate-limiting step for ECM class 2 compounds. The overall  hepatic uptake 
(sum of active and passive) is projected to be rate-determining for ECM class 3 compounds, whereas the 
overall intrinsic clearance of ECM class 4 compounds is dependent on the interplay of all processes 
involved in hepatic elimination (namely metabolism, uptake, and efflux). 
 
 
Figure 1. Rate-determining hepatic clearance processes (inner panels) derived from the extended clearance model 
(ECM) based on different pre-requisites (outer panels) and the assumption thyat PSeff,pas is equal to PSinf,pas and that 
PSeff,act equals zero (Eq. (1)). 
 
Viewing the liver as a single compartment and assuming that drug molecules are distributing 
instantaneously and homogeneously within the liver upon entering (well-stirred liver model) the hepatic 
blood clearance (CLh) can be calculated with: 
 
𝐶𝐿ℎ =
𝑄ℎ ∙ 𝑓𝑢 ,𝑏 ∙ (𝑃𝑆𝑖𝑛𝑓 ,𝑎𝑐𝑡 + 𝑃𝑆𝑖𝑛𝑓 ,𝑝𝑎𝑠 ) ∙ (𝐶𝐿𝑖𝑛𝑡 ,𝑚𝑒𝑡 + 𝐶𝐿𝑖𝑛𝑡 ,𝑠𝑒𝑐 )
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where Qh is the hepatic blood flow (20.7 mL/(min·kg)) and fu,b is the unbound fraction in blood. The 
clearance parameters of the extended clearance model can be determined experimentally as discussed in 
full detail elsewhere [1,3]. In brief, PSinf,act and PSinf,pas can be assessed by uptake experiments in suspended 
human hepatocytes (SHH), CLint,sec can be determined in human sandwich-cultured hepatocyte incubations 
(generally assuming that metabolism in this system is negligible) whereas CLint,met, assuming absence of 
non-oxidative metabolism, is usually experimentally evaluated in human liver microsomal (HLM) 
incubations. Efflux over the sinusoidal membrane from hepatocytes back into the blood is frequently 
assumed to occur via passive diffusion only (i.e. PSeff,act = 0). The experimental determination of this 
parameter is difficult. In the absence of measured data, the passive sinusoidal efflux is usually assumed to 
be equal to the passive influx (i.e. PSeff,pas = PSinf,pas). The individual clearances can finally be fed into Eq. (1) 
and Eq. (2) to predict CLh,int  and CLh of a drug. Table 1 provides a compilation of experimentally determined 
intrinsic clearances for a dataset of 19 physicochemically diverse compounds from the literature together 
with corresponding in vivo reference data and the ECM classification according to Fig. 1 [1, 4-7]. 
Table 1. Experimental human hepatic process clearances from in vitro assays and corresponding in vivo reference 
data. 
 Experimental in vitro data In vivo reference data 
compounds ECM/ECC PSinf,act 
PSeff = 
PSinf,pas 
CLint,met,HLM CLint,met,HH CLint,sec fu,b CLh,obs fnren fnmet 
 - mL/(min·kg) mL/(min·kg) mL/(min·kg) mL/(min·kg) mL/(min·kg) -  mL/(min·kg) - - 
lovastatin acid 3/1 165.1 145.5 459.0 119.6 0.0 0.08 11.4 0.10 0.90 
simvastatin acid 3/1 116.1 297.9 769.2 ND 1.7 0.11 25.2 0.13 0.87 
propanolol 4/2 300.7 276.3 110.8 29.2 6.8 0.11 12.8 0.01 0.99 
quinidine 4/2 229.4 109.3 28.4 18.0 5.1 0.27 8.7 0.19 0.81 
verapamil 2/2 0.0 258.2 127.7 33.4 8.1 0.13 13.7 0.03 0.97 
ketoconazole 2/2 0.0 1568.5 97.4 ND 29.6 0.02 3.9 0.03 0.97 
cerivastatin 4/2 221.5 243.8 46.9 ND 0.0 0.02 3.4 0.00 1.00 
fluvastatin 4/2 218.7 325.5 146.8 ND 0.0 0.04 7.0 0.00 1.00 
pitavastatin 4/2 364.3 258.7 17.7 ND 0.0 0.07 3.5 0.00 ND 
aliskiren 3/3 32.3 25.4 89.2 ND 31.2 0.70 11.3 0.25 0.10 
cimetidine 3/3 3.0 3.6 528.7 3.2 0.2 0.84 2.7 0.84 0.14 
digoxin 3/3 20.0 6.9 24.2 ND 18.4 0.82 4.6 0.66 0.04 
cyclospsorine A 3/4 113.2 41.9 77.6 13.5 9.1 0.03 3.1 0.01 0.96 
atorvastatin 4/4 140.4 57.7 64.6 254.4 11.8 0.08 5.9 0.02 0.69 
 
furosemide 4/4 11.1 23.9 19.0 0.9 1.2 0.03 0.4 0.66 0.01 
ciprofloxacin 4/4 7.0 22.9 22.0 ND 0.0 0.69 4.5 0.60 0.12 
valsartan 4/4 16.0 18.5 4.1 ND 21.5 0.09 0.6 0.29 0.11 
pravastatin 4/4 57.9 36.0 0.9 5.3 2.2 0.97 10.4 0.47 0.30 
rosuvastatin 4/4 27.2 24.8 1.5 ND 5.7 0.17 ND 0.30 0.10 
ND: Not determined or experimental data subject to a high degree of uncertainty as discussed elsewhere [4]. With exception of the 
hepatocyte turn-over data [5,6] all hepatic in vitro and in vivo data were taken from previous in-house manuscripts [1,4,7]. ECM and 
ECC class assignment was performed according to Fig. 1 and Fig. 6, respectively (underlying working principle: class 1 or 3 if 2·PSeff < 
(CLint,met,HLM + CLint,sec), otherwise class 2 or 4). Metabolic clearance data from human liver microsomes and human hepatocytes are 
labeled with the subscripts HLM and HH, respectively. fnmet (= CLmet,obs/CLtot,obs) and fnren (= CLren,obs/CLtot,obs) values were calculated 
from the observed total (CLtot,obs), renal (CLren,obs) and metabolic (CLmet,obs) clearances as derived from peroral human mass balance 
studies taking into consideration the estimated absolute oral bioavailability (F). Thereof, fnh (=1- fnren) and fnsec (= fnh- fnmet) values 
discussed in this manuscript can be calculated.  
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Role of membrane permeability in hepatic elimination 
The likelihood that drugs will be subject to enzyme and/or canalicular efflux transporter activities in the 
liver depends on the extent of their sinusoidal membrane permeation. For the compounds in our dataset 
(Table 1) this is illustrated in Fig. 2 depicting the relationship between (in vitro) sinusoidal passive uptake 
(PSinf,pas) and the fractional contribution of metabolism (fnmet, panel A) or biliary secretion (fnsec, panel B) to 
overall in vivo elimination. 
 
Figure 2. Correlation of sinusoidal hepatic uptake clearances (PSinf,pas or PSinf) with the fractional contributions of 
metabolic (panel A), biliary (panel B), hepatic (panel C) and renal (panel D) clearance to overall in vivo elimination. 
 
An increase in lipophilicity is well known to promote the passive permeability potential of drugs as well 
as their affinity to drug metabolizing enzymes [8]. Above observed inter-relationship, as depicted in Fig. 2 
(panel A), is therefore not very surprising. The association of permeability and enzyme activity allows to 
define an approximate sinusoidal permeability threshold above which drug elimination seems 
predominantly driven by metabolism (> 200 mL/(min·kg)). The corresponding plot of PSinf,pas vs fnsec reveals 
that compound recognition by canalicular efflux transporters, in contrast to fnmet, is by some means 
inversely correlated with rising sinusoidal permeability (Fig. 2, panel B). Fig. 3 shows the contribution of the 
measured in vivo metabolic clearance to the in vivo hepatic clearance (= fnmet/fnh) for the compounds in 
our dataset. Not astonishingly, the compounds with a high (total) sinusoidal permeability are 
predominantly cleared via hepatic metabolism, while the contribution of metabolism generally decreases 
for lower permeability compounds apparently accompanied by an increasing contribution of active 
canalicular secretion.  
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Figure 3. Contribution of in vivo metabolism to overall hepatic clearance for the dataset in Table 1. The dotted line 
separates the high permeability compounds (green bars) from the low permeability drugs (orange bars) as determined 
by uptake experiments in suspended hepatocytes (PSinf threshold: 200 mL/(min·kg)). 
 
Hepatic versus non-hepatic elimination 
Figure 2 (panel C) illustrates the relationship between passive sinusoidal uptake (PSinf,pas) and the 
observed (in vivo) fractional contribution of hepatic clearance to overall drug elimination fnh. From this 
illustration it appears that a sinusoidal permeability of above 40-60 mL/(min·kg) will result in predominant 
hepatic clearance (> 80 %). Numerous data demonstrates that permeability also exerts a key role in renal 
elimination similar to the one discussed here for liver [4]. It could be demonstrated that for the highly 
permeable compounds, despite significant tubular secretion, reabsorption from the tubule back into the 
blood is so extensive that overall renal clearance for these compounds will be low. For the low permeable 
compounds on the other hand reabsorption, in agreement with their reduced permeability potential, will 
be much less. As illustrated in Fig. 4, for all compounds in our dataset with a (passive) sinusoidal 
permeability beyond 40 mL/(min·kg) renal clearance is a minor route of elimination (fnren < 20 %). For the 
lower permeable compounds the fractional contribution of renal clearance to total body clearance exceeds 
20% or even represents the predominant route of elimination suggesting that hepatic and renal 
elimination are somehow complementary with regards to the role of sinusoidal permeability in drug 
elimination. 
 
Figure 4. Contributions of the observed renal (red bars) and hepatic (blue bars) clearance pathways to the total body 
clearance (CLtot,obs = CLh,obs + CLren,obs) for the compounds in Table 1. The dotted line separates the compounds with a 
PSinf,pas value greater (left part) or lower (right part) than 40  mL/(min·kg)). 
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Fig. 2 (panel D) illustrates the relationship between fnren and total sinusoidal uptake (PSinf) for the 
present dataset. As discussed above, a low permeability is hindering hepatic elimination pushing drugs 
towards alternative elimination routes (with decreasing lipophilicity plasma protein binding usually 
decreases which would result in increased glomerular filtration process, possibly increased active tubular 
secretion and less reabsorption) [4]. Beyond a PSinf value of 100 mL/(min·kg)) renal elimination becomes 
very unlikely. Consequently, following integration of the information from this and the previous chapter, it 
becomes apparent that total sinusoidal uptake is THE predominant gatekeeper between almost exclusive 
metabolic hepatic elimination (> 200 mL/(min·kg)), mixed hepatic (metabolism plus biliary secretion,  
100-200 mL/(min·kg)) and mixed hepatic/renal elimination (metabolism plus biliary and urinary secretion, 
< 100 mL/(min·kg)) (Fig. 5). Exclusive renal clearance is expected only if PSinf is approaching a very low value 
or if substantial entero-hepatic circulation is taking place. Yet, renal excretion might become the 
predominant elimination pathway for low permeable compounds with about PSinf < 30 mL/(min·kg) (Fig. 2, 
panel D). For compounds with sinusoidal uptake between 30-60 mL/(min·kg), mixed urinary/biliary 
elimination seems to be the most probable clearance pathway. Consequently, the relationship between 
PSinf,pas and fnsec as shown in Figure 2 (panel B) likely needs to be interpreted as a bell-shaped curve with a 
PSinf,pas maximum at around 30 mL/(min·kg) (maximal fnsec ≈ 0.6-0.7).  
 
 
Figure 5. Schematic illustration of the change in elimination route as a function of sinusoidal uptake (PSinf). fnmet, fnren 
and fnsec denote the fractional contributions of (hepatic) metabolic, urinary and biliary elimination to overall clearance, 
respectively. Above a PSinf threshold of about 60 mL/(min·kg) liver is the expected primary clearance organ whereas 
below 30 mL/(min·kg) renal elimination is likely predominant. 
 
Extended Clearance Concept Classification System 
The extended clearance concept (ECC) is the intangible attempt to complete the principles of the 
extended clearance model (Fig. 1) with the gatekeeping role of sinusoidal influx as discussed above (Fig. 5) 
to allow prediction of in vivo pharmacokinetic performance of drugs from in vitro permeability and 
metabolism data as illustrated in Fig. 6. Drugs with a high apparent hepatic intrinsic clearance are removed 
from the blood essentially as fast as they can be delivered to the liver, i.e. independent of protein binding 
and intrinsic enzyme and canalicular efflux transporter activities. Therefore, the elimination of such drugs is 
highly dependent upon liver blood flow and the inherent ability to cross the sinusoidal membrane rapidly. 
Consequently, according to the well-stirred liver model, a compound can be ranked as highly permeable if 
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CLh,int = PSinf,pas >> Qh (Eq. (1) and Eq. (2)). From above discussion it is evident that a (passive) sinusoidal 
permeability above 60 mL/(min·kg) results in an almost complete hepatic clearance (Fig. 2, panel C and Fig. 
5). Thus, a compound can be ranked as highly permeable if PSinf,pas ≥ 3-fold Qh, a threshold substantiating 
the conceptual approximation PSinf ≈ PSeff ≈ PSinf,pas pertinent to all compounds identified to be hepatic 
uptake transporter substrates besides demonstrating a high intrinsic permeation potential across the 
sinusoidal membrane of hepatocytes. Hence, it becomes evident that uptake transporter effects for highly 
permeable compounds are minimally contributing to overall hepatic clearance while they are expected to 
become important/predominant for the hepatic clearance of lower permeable compounds. Applying this 
fundamental relationship, the 19 compounds in our dataset were assigned to the four different ECC classes 
as summarized in Table 1. 
 
Figure 6. Predominant routes of drug elimination and potential transporter effects on (hepatic) drug disposition 
according to the Extended Clearance Concept Classification System (ECCCS). Thresholds as defined by the 
Biopharmaceutics Drug Disposition Classification system (BDDCS) are provided for comparative reasons also [1,8]. 
 
Taking all above principles into account it is appropriate to conclude that the major route of elimination 
for ECC class 3 and 4 compounds is renal and biliary excretion of unchanged drug whereas metabolism is 
the predominant elimination pathway for ECC class 1 and 2 compounds as previously concluded by others 
also [8]. However, ECC allows a compound classification of drug molecules based on their in vitro 
determined (hepatic) clearance parameters in contrast to the Biopharmaceutics Drug Disposition 
Classification System (BDDCS) which allocates drugs into four classes according to their in vivo metabolism 
and solubility potential. Both concepts are closely related and have in common that they recognize that the 
fundamental parameter controlling (hepatic) drug disposition is the compound class-dependent interplay 
between transporters, enzymes and membrane permeability. Both systems provide a similar rational on 
the predominant routes of drug elimination and the potential effect of transporters on (hepatic) drug 
disposition as illustrated in Fig. 6. Yet, assignment into BDDCS relies on clinical elimination information and 
is therefore not really applicable for early Drug Development.  
Camenisch et al.  ADMET & DMPK 3(1) (2015) 1-14 
8  
ECC and IVIVE 
The correlation between the in vitro predicted (CLh,pred) and in vivo observed (CLh,obs) hepatic clearances 
for our dataset based on the mechanistic in vitro-in vivo extrapolation (IVIVE) method represented by Eq. 
(1) and Eq. (2) is illustrated in Fig. 7 (panel A). The approach reveals an excellent correlation with 11 out of 
18 drugs predicted within two-fold deviation from the clinically observed value. The prediction accuracy in 
terms of average fold error (afe) and geometric mean fold error (gmfe) was 0.92 and 1.55, respectively. 
Present results demonstrate that the extended clearance concept model is by far exceeding the accuracy 
and performance of other IVIVE prediction methods for hepatic clearance based only on in vitro 
metabolism (Fig. 7, panels B and C for microsomes (afe = 0.76, gmfe = 2.11)) and hepatocytes (afe = 0.32, 
gmfe = 3.56), respectively) or sinusoidal uptake (Fig. 7, panel D, afe = 1.71, gmfe = 1.84) data. 
 
Figure 7. Comparison of the reported (CLh,obs) and predicted (CLh,pred) hepatic clearances using different IVIVE methods. 
Panel A represents the relationship according to the extended clearance model (ECM). The panels B and C show the 
predictions based on in vitro metabolism data from human microsomes (HLM) and hepatocytes (HH), respectively, 
whereas panel D is the representation based on sinusoidal uptake data from suspended human hepatocytes (SHH). 
Red diamonds, green squares, blue triangles and orange circles show the class 1, 2, 3 and 4 assignments according to 
ECC (Table 1). The blue line represents the line of unity for each panel. 
 
In accordance with previous research, the correlation analysis in Fig. 7 reveals a systematic under-
prediction of in vivo hepatic clearance when using metabolic turn-over data from human hepatocyte 
incubations whereas sinusoidal uptake data from suspended human hepatocytes tend to over-predict the 
in vivo situation [9,10]. Metabolic clearance data from human liver microsomes on the other hand are 
highly scattered along the line of unity providing under- and over-estimations of the observed human 
hepatic clearance. The potential rate-determining role of the hepatocyte membrane (missing in the 
microsomal system) is extensively discussed in literature. In line with this theory more in-depth data 
examination reveals that metabolism information from microsomes and hepatocytes generally provide 
reasonable results for the ECC class 1 and 2 compounds while hepatocyte uptake data seem to be highly 
predictive for the in vivo hepatic clearance of ECC class 3 compounds. IVIVE based on the extended 
mechanistic model surely works best for ECC class 4 compounds though. Imposing these observations on 
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the principles of ECC the expected performance of the different IVIVE approaches can be summarized as 
depicted in Fig. 8. It is self-explanatory that with increasing contribution of renal clearance the 
predictability of all hepatobiliary IVIVE tools for overall (total) clearance is decreasing (tendency for 
underestimation). Based on above discussion, this is mainly true for ECC class 3 and 4 compounds while the 
overall prediction performance for ECC class 1 and 2 compounds likely remains good. In-house research 
intending to improve bottom-up predictions for overall human clearance using different in vitro and in vivo 
approaches is currently ongoing. 
 
Figure 8. Anticipated hepatobiliary IVIVE accuracy of different in vitro tools: Metabolism assessment in human liver 
microsomes (HLM) or human hepatocytes (HH), uptake data from suspended human hepatocytes (SHH) and 
integrated approach with the extended clearance model (ECM). For the assignment the following assumptions were 
made: (i) absence of significant biliary secretion (i.e. CLint,sec << CLint,met), (ii) absence of phase II metabolism and, (iii) no 
or down-regulated transporter activity in HH. 
 
Static DDI predictions 
A perpetrator drug may inhibit any active clearance pathway contributing to the total hepatic 
elimination of a substrate. Accordingly, based on Eq. (1) (assuming PSeff,act = 0 and PSeff,pas = PSinf,pas), the 
overall hepatic intrinsic clearance in the presence of a perpetrator (CLh,int,i) can be expressed as follows 
[1,7]: 
 
𝐶𝐿ℎ ,𝑖𝑛𝑡 ,𝑖 =
 1− 𝑓𝑖 ,𝑖𝑛𝑓  ∙ 𝑃𝑆𝑖𝑛𝑓 ,𝑎𝑐𝑡 + 𝑃𝑆𝑖𝑛𝑓 ,𝑝𝑎𝑠  ∙ [ 1− 𝑓𝑖 ,𝑚𝑒𝑡  ∙ 𝐶𝐿𝑖𝑛𝑡 ,𝑚𝑒𝑡 + (1− 𝑓𝑖 ,𝑠𝑒𝑐 ) ∙ 𝐶𝐿𝑖𝑛𝑡 ,𝑠𝑒𝑐 ]




where fi,inf, fi,sec and fi,met denote the inhibited fractions of active influx, canalicular secretion, and 
metabolism, respectively. A fi value of zero thereby indicates no inhibition whereas a value of one refers to 
(3) 
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complete inhibition. Based on this relationship the hepatic clearance in the presence of any perpetrator 
compound (CLh,i) can be anticipated in accordance with Eq. (2). 
Following oral (po) administration of a drug and its perpetrator, assuming the presence of  hepatic and a 
non-hepatic (e.g. renal) elimination pathways and that the perpetrator drug only affects active processes in 









𝑓𝑛ℎ ∙ 𝐶𝐿ℎ ,𝑖 𝐶𝐿ℎ + 1− 𝑓𝑛ℎ
 
 
where, Fh (= 1-CLh/Qh) and Fh,i (= 1-CLh,i/Qh) are the fractions of the oral dose escaping hepatic first-pass in 
the absence and presence of a perpetrator, respectively. 










In an abbreviated manner, based on Eq. 5 and previous discussion, the drug-drug interaction (DDI) 
potential for the four ECM cases in Fig. 1 can therefore be represented as shown in Fig. 9.  
 
 
Figure 9. Compound class-dependent DDI prediction (inner panel) according to Eq. 5 for the four different ECM cases 
based on different pre-requisites (outer panel). i refers to a change in clearance in the presence of any perpetrator 
compound. 
Fig. 10 depicts the predicted static DDI risk assessment of 3 representative compounds from our dataset 
(namely the ECM class 2 compound verapamil, digoxin as a typical ECM class 3 compound and pravastatin 
representing the ECM class 4) according to Eq. (4) and Eq. (5), assuming 90% inhibition of the respective 
(4) 
(5) 
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processes (i.e. fi,inf = fi,met = fi,sec = 0.9, not taking into consideration fractional contributions of different 
enzymes or transporters to overall metabolic or transport clearance). In the absence of a renal clearance 
contribution (Fig. 10, panel A), in accordance with the extended clearance model, for the ECM class 2 
compound in our selection, metabolism is identified as the major clearance mechanism primarily 
responsible for causing DDI’s. Selective inhibition of active hepatic influx or biliary secretion has no 
significant effect on exposure though. A similarly distinct overall DDI behavior can be derived for the ECM 
class 3 compound digoxin with sinusoidal transporter inhibition being the major mechanism causing the 
interaction. For the ECM class 4 compound pravastatin, assuming absence of a renal clearance 
contribution, we predict a substantial AUC change upon concomitant inhibition of hepatic uptake, biliary 
secretion and metabolism whereas inhibition of the single clearance pathways results in comparatively 
moderate AUC ratios. Taking the clinically observed fnh values according to Eq. (4) into account, the 
individual as well as the overall DDI risk assessment of verapamil is only marginally effected whereas the 
impact on the projected exposure changes for digoxin and pravastatin is significant (e.g. the overall 
AUCpo,i/AUCpo ratio for pravastatin decreases about 8-fold) (Fig. 10, panel B). This concept is well reflected 
by ECM and can be rationalized by the process inter-dependencies as discussed above. It is noteworthy to 
mention at this point, that the extended clearance model represents the four extremes of hepatobiliary 
elimination and that most drugs settle somewhere in-between the ultimate limits given in Fig. 1. To 
eventually predict the overall DDI potential of drug molecules it is therefore essential to (quantitatively) 
assess all the individual hepatic process contributions as defined by Eq. (1). 
 
 
Figure 10. Static victim drug DDI predictions for verapamil (CYP2C8, CYP3A and P-gp), digoxin (P-gp, CYP3A and 
unknown sodium-dependent sinusoidal uptake transporter) and pravastatin (BCRP, MRP2, OATP1B1, OATP1B3, 
OATP2B1 and CYP3A4) according to Eq. (5) (panel A) and Eq. (4) (panel B). The projected AUC fold-changes with fi,inf = 
fi,met = fi,sec = 0.9 are represented as follows: metabolism inhibition only (blue bars), exclusive sinusoidal active uptake 
inhibition (red bars), inhibition of canalicular efflux (light green bars) and, simultaneous inhibition of all active 
processes together (yellow bars). 
 
Neglecting time-dependent concentration changes, static DDI predictions are expected to provide 
conservative (worst-case) estimates for the effective in vivo situation [1]. Nevertheless, DDI assessments 
according to Eq. (4) are generally in good agreement with clinical DDI data for ECM class 1 and 2 
compounds as discussed elsewhere [7]. However, with increasing fnren (i.e. decreasing fnh), the predictions 
become less reliable for ECM class 3 and 4 compounds, often resulting in significant under-estimations of 
the effective DDI risk observed in clinics (e.g. pravastatin exposure in the presence of cyclosporine A 
(inhibitor of OATP’s, OAT’s, NTCP, P-gp, BCRP, MRP2, CYP3A4 and UGT’s) was reported to increase about 
20-fold, significantly exceeding the theoretically possible hepatic DDI potential of 2.6-fold (Fig. 10)) [7]. The 
main reason for this observation is that a significant renal secretion process for these low permeable 
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compounds is typically governed by active transporter processes which often are concomitantly inhibited 
by perpetrator drugs also interfering with the sinusoidal uptake carrier system in the liver. Consequently, 
for conservative bottom-up DDI estimates the physiologically less appropriate Eq. (5) should be preferred 
as it accommodates for possible cross-reactivity on hepatic and renal (transporters) systems (e.g. the 
clinical observation for pravastatin in the presence of cyclosporine A is well predicted with Eq. (5) (Fig. 10)).  
Nevertheless, in combination with clinical DDI data and applying a top-down approach, comparative static 
DDI assessments according to Eq. (4) and Eq. (5) can be extremely helpful in revealing alternative (extra-
hepatic) active elimination processes as discussed in full detail elsewhere [7]. 
 
Prediction of unbound intracellular hepatic drug concentrations 
 
Figure 11. ECM class-dependent effect on the unbound liver-to-capillary blood concentration ratio (Kpuu) according to 
Eq. 6. 
 
According to the so-called free drug hypothesis, at steady-state and in the absence of a membrane 
transport barrier limiting access to the hepatocyte, the unbound (free) intracellular concentration Ch,u is 
equal to  the unbound blood concentration Cb,u (i.e. Ch,u/Cb,u = 1). However, according to the extended 
clearance model, Ch,u is not only governed by uptake and protein binding but also by all intracellular 












ADMET & DMPK 3(1) (2015) 1-14 Extended Clearance Concept Classification System (ECCCS) 
doi: 10.5599/admet.3.1.144 13 
where, Kpuu is the unbound liver-to-capillary blood concentration ratio. In line with ECM, the impact of the 
relative process contributions on Kpuu can be summarized as shown in Fig. 11. The knowledge of the 
relevant (effective) intrahepatic concentrations is important when performing DDI risk assessments 
(compound acting as inhibitor) on active processes such as metabolism and/or canalicular efflux. However, 
due to experimental inaccessibility of Ch,u, static perpetrator risk calculations for the liver generally refer to 
Cb,u (usually expressed as Cb,u /Ki, where Ki denotes the inhibition constant on a particular process). Based 
on the extended clearance model it becomes evident that the use of this substitute might lead to a 
considerable misjudgment of the DDI potential of perpetrator drugs though. Depending on the major rate-
determining process driving hepatic elimination significant under- (e.g. Kpuu equals 2.4 for ECM class 4 
compound pravastatin) or over- (e.g. Ch,u is about 80-fold less than Cb,u for ECM class 3 compound 
cimetidine) estimations of the real interaction risk might result. The use of systemic unbound drug 
concentrations (or unbound drug concentrations in the portal vein) is thus likely insufficient to properly 
assess the actual drug-drug interaction potential on intracellular enzymes/transporters for class 1, 3 and 4 
compounds as illustrated in Table 2. 
Table 2. Effect of Kpuu on Ch,u and the DDI risk outcome for perpetrator drugs. 
ECM class Effect of Kpuu on Ch,u (Eq. (6)) Risk assessment with Cb,u /Ki 
1 Ch,u << Cb,u overestimation 
2 Ch,u = Cb,u predictive 
3 Ch,u < or > Cb,u under- or overestimation (generally overestimation as usually PSinf < CLint) 
4 Ch,u < or > Cb,u under- or overestimation (generally underestimation as usually PSinf > PSeff) 
 
Although currently not requested by health authorities present ECM-based principles might change the 
way we are doing perpetrator DDI risk assessments for intracellular hepatic processes in the future, all the 
more the mechanistic IVIVE method presented in this manuscript was demonstrated to provide 
quantitative reliable estimates of CLh,obs and therewith of Kpuu (see above). Further in-house research on 
this this topic is currently ongoing. 
 
Conclusions 
In this review, we have illustrated the usefulness of the extended clearance model for classifying drug 
compounds depending on the relative contributions of the individual hepatic elimination processes. The 
ECM classification system based upon easily accessible in vitro data for metabolism, sinusoidal transport 
and canalicular efflux allows the quantitative bottom-up assessment of a series of (pharmacokinetic) 
parameters such as the hepatic clearance, the unbound liver-to-capillary blood concentration ratio and the 
static prediction of the DDI potential of drug molecules. The method reveals the major role of sinusoidal 
uptake as a gatekeeper for drug elimination, provides insight into the performance of different IVIVE 
approaches for hepatic clearance prediction and highlights potential limitations of currently applied drug-
drug interaction risk assessment approaches. Consequently, following a thoughtful implementation, the 
approach may facilitate the compound selection process in Pharmaceutical Research and improve some of 
the compound profiling methodologies (e.g. DDI risk assessment) applied in Drug Development. 
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